Presentations & Publications
AACR Poster Presentation - High prevalence of immune exclusion in cancer as determined by pathologist assessment and image analysis
April 17-18, 2023
Stifel Healthcare Conference - Attacking Immune Exclusion and Resistance to IO Therapy Using Evidence-based Drug Design against Barriers in the Tumor Microenvironment
November 15-16, 2022
SITC 2022 Conference - Discoidin Domain Receptor 1 Expression is Associated with Stroma TGF-beta Signaling in Selected Cancers
November 10, 2022
BioFuture 2022 - Featured Speaker
November 9, 2022
Oncology Strategy Meeting 2022 Cambridge - Keynote: Drugging the Tumor Microenvironment to Achieve Durable Response in Patients
November 8, 2022
Path AI/Fierce Biotech Webinar - Unlocking the Tumor Microenvironment with PathAI
October 26, 202
Immuno-Oncology Summit - Novel Strategies for Targeting the Tumor Microenvironment: First-in-Class Monoclonal Antibody Targeting a Specific Domain of Collagen Receptor Discoidin Domain Receptor-1 (DDR1)
October 13-14, 2022
LabCentral Ignite - Life Sciences in Full Color Campaign
September 28, 2022
Spatial Biology US - Panel: Adopting Spatial Technologies: Challenges & Opportunities
September 16, 2022
TMCi Accelerator for Cancer Therapeutics Program - Next Generation Monotherapy Designed to Reengineer the Tumor Microenvironment in Immune-Excluded Tumors
September 15, 2022
LabCentral Ignite - Panel: Career Pathways in Biotech: Finding Your Fit
July 7, 2022
Extracelluar Matrix Pharmacology Congress - Overcoming Tumor Immune-Exclusion by DDR1 Blockade with PRTH-101
June 23-25, 2022
Targeted Oncology Conference - Breaking Down Barriers in Immune-Excluded Tumor Biology
June 14, 2022
Endpoints at #Bio22 - BioPharma at the Crossroads - Panel: Cell Therapy 2.0: The New Frontier Confronts New Safety Threats
June 13, 2022
Biomarker Insights Summit - Characterization of Immune-Excluded Tumors by Multiplex Immunoflourescence for Precision Oncology Applications
April 8, 2022
Oppenheimer 32nd Annual Healthcare Conference - Attacking Immune Exclusion and Resistance to IO Therapy Using Evidence-based Drug Design against Barriers in the Tumor Microenvironment
March 16, 2022
European Association for Cancer Research - Breaking Down Barriers in the Tumor Microenvironment with a First-in-Class Therapeutic Antibody Targeting Immune-excluded Tumors
February 23, 2022
ESMO Congress 2022 - Cancer-Associated Fibroblasts correlate with Immune Phenotypes in Human Tumors
September 9-13, 2022
Published Article in Nature: "Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion"
November 3, 2021
Investor Contact:
Argot Partners
212-600-1902
parthenon@argotpartners.com
40 Guest St.
Boston, MA 02135
617.870.3363
© 2022 Parthenon Therapeutics Inc. All rights reserved.
40 Guest St.
Boston, MA 02135
617.870.3363